Abstract：
The rise of multidrug-resistant bacteria is a well-recognized threat to world health, necessitating the implementation of effective treatments. This issue has been identified as a top priority on the global agenda by the World Health Organization. Certain strains, such as Candida glabrata, Candida krusei, Candida lusitaniae, Candida auris, select cryptococcal species, and opportunistic Aspergillus or Fusarium species, have significant intrinsic resistance to numerous antifungal medicines. This inherent resistance and subsequent suboptimal clinical outcomes underscore the critical imperative for enhanced therapeutic alternatives and management protocols. The challenge of effectively treating fungal infections, compounded by the protracted timelines involved in developing novel drugs, underscores the pressing need to explore alternative therapeutic avenues. Among these, drug repurposing emerges as a particularly promising and expeditious solution, providing cost-effective solutions and safety benefits. In the fight against life-threatening resistant fungal infections, the idea of repurposing existing medications has encouraged research into both established and new compounds as a last-resort therapy. This chapter seeks to provide a comprehensive overview of contemporary antifungal drugs, as well as their key resistance mechanisms. Additionally, it seeks to provide insight into the antimicrobial properties of non-traditional drugs, thereby offering a holistic perspective on the evolving landscape of antifungal therapeutics.
摘要：
多重耐药细菌的上升是公认的对世界健康的威胁，需要实施有效的治疗。这一问题已被世界卫生组织确定为全球议程上的最高优先事项。某些菌株，如光滑念珠菌，克鲁斯念珠菌,念珠菌,耳念珠菌,选择隐球菌物种，和机会性曲霉或镰刀菌，对许多抗真菌药物有显著的内在耐药性。这种固有的耐药性和随后的次优临床结果强调了增强治疗替代方案和管理方案的关键必要性。有效治疗真菌感染的挑战，加上研发新药的时间过长，强调了探索替代治疗途径的迫切需要。其中,药物再利用成为一种特别有希望和迅速的解决方案，提供具有成本效益的解决方案和安全利益。在对抗危及生命的耐药性真菌感染的斗争中，重新利用现有药物的想法鼓励了对已建立和新化合物作为最后手段的研究。本章旨在提供当代抗真菌药物的全面概述，以及它们的主要抵抗机制。此外,它旨在深入了解非传统药物的抗菌特性，从而为抗真菌疗法的发展提供了一个整体的视角。
